An attempt of specific desensitising treatment with gliadin in celiac disease.
Gluten-free diet is the current treatment of celiac disease. We decided to verify the occurrence of histological and serological modification and/or clinical manifestations during a gradual and progressive introduction of gliadin in the diet and if it may induce a tolerance to food, as it occurs in allergic patients. We studied the case of a celiac woman with complete clinical and histological remittance after 10 years of gluten free diet. She took increasing daily doses of gliadin, reaching the final dose of 9 g of gliadin (15 g of gluten) in 6 months. Then she started a free dietary regimen. During the 15-month follow-up period esophago-gastro-duodenoscopy showed normal Kerckring folds and villi. Anti-gliadin, anti-endomysium and anti-tissue-transglutaminase antibodies, as well as the haematological and biochemical parameters remained normal. Our results represent a new approach in research concerning celiac disease, and could provide a future line of study for its management.
Patriarca
G
G
Allergology Department, Catholic University Policlinico Gemelli, Rome, Italy. allergologia@hotmail.com
Pogna
N
N
Cammarota
G
G
Schiavino
D
D
Lombardo
C
C
Pollastrini
E
E
De Pasquale
T
T
Buonomo
A
A
Nocente
F
F
Gazza
L
L
Pietrini
D
D
Miele
L
L
Nucera
E
E
Gasbarrini
G
G
D000328:Adult; D000906:Antibodies / Q000032:analysis; D002446:Celiac Disease / Q000178:diet therapy* / Q000473:pathology; D003888:Desensitization, Immunologic; D004386:Duodenum / Q000473:pathology; D004724:Endoscopy; D005260:Female; D005500:Follow-Up Studies; D005903:Gliadin / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis / Q000096:biosynthesis; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology; D011503:Transglutaminases / Q000276:immunology
D000906:Antibodies; D007073:Immunoglobulin E; D005903:Gliadin; D011503:Transglutaminases